JAMA Cardiology
Original Investigation
February 21, 2024
Michael T.ÌýLu, MD, MPH; Heather Ribaudo, PhD; Borek Foldyna, MD; Markella V.ÌýZanni, MD; Thomas Mayrhofer, PhD; Julia Karady, MD, PhD; Jana Taron, MD; Kathleen V.ÌýFitch, MSN; Sara McCallum, MPH; Tricia H.ÌýBurdo, PhD; Kayla Paradis, MBA; Sandeep S.ÌýHedgire, MD; Nandini M.ÌýMeyersohn, MD; Christopher DeFilippi, MD; Carlos D.ÌýMalvestutto, MD, MPH; Audra Sturniolo, MS; Marissa Diggs, BA; Sue Siminski, MBA; Gerald S.ÌýBloomfield, MD; Beverly Alston-Smith, MD; Patrice Desvigne-Nickens, MD; Edgar T.ÌýOverton, MD; Judith S.ÌýCurrier, MD; Judith A.ÌýAberg, MD; Carl J.ÌýFichtenbaum, MD; Udo Hoffmann, MD, MPH; Pamela S.ÌýDouglas, MD; Steven K.ÌýGrinspoon, MD; REPRIEVE Trial Writing Group
open access
has multimedia
JAMA Cardiol. 2024; 9(4):323-334. 10.1001/jamacardio.2023.5661
This substudy of a randomized clinical trial investigates the effects of pitavastatin on noncalcified coronary artery plaque using coronary computed tomography angiography and on inflammatory biomarkers as potential mechanisms for major adverse cardiovascular event prevention.
JAMA
Original Investigation
June 3, 2021
Myron S.ÌýCohen, MD; Ajay Nirula, MD, PhD; Mark J.ÌýMulligan, MD; Richard M.ÌýNovak, MD; Mary Marovich, MD; Catherine Yen, MD; Alexander Stemer, MD; Stockton M.ÌýMayer, DO; David Wohl, MD; Blair Brengle, MD; Brian T.ÌýMontague, DO; Ian Frank, MD; Russell J.ÌýMcCulloh, MD; Carl J.ÌýFichtenbaum, MD; Brad Lipson, DO; Nashwa Gabra, MD; Julio A.ÌýRamirez, MD; Christine Thai, MD; Wairimu Chege, MD, MPH; Margarita M.ÌýGomez Lorenzo, MD; Nirupama Sista, PhD; Jennifer Farrior, MS; Meredith E.ÌýClement, MD; Elizabeth R.ÌýBrown, ScD; Kenneth L.ÌýCuster, PhD; Jacob Van Naarden, BS; Andrew C.ÌýAdams, PhD; Andrew E.ÌýSchade, MD, PhD; Matan C.ÌýDabora, MD; Jack Knorr, PhD; Karen L.ÌýPrice, PhD; Janelle Sabo, PharmD; Jay L.ÌýTuttle, PhD; Paul Klekotka, MD, PhD; Lei Shen, PhD; Daniel M.ÌýSkovronsky, MD, PhD; BLAZE-2 Investigators
free access
is active quiz
JAMA. 2021; 326(1):46-55. 10.1001/jama.2021.8828
This randomized clinical trial assesses the effect of a single intravenous infusion of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities.
ÁñÁ«ÊÓƵ Network Open
Original Investigation
Cardiology
June 29, 2021
Udo Hoffmann, MD, MPH; Michael T.ÌýLu, MD, MPH; Borek Foldyna, MD; Markella V.ÌýZanni, MD; Julia Karady, MD; Jana Taron, MD; Bingxue K.ÌýZhai, MS; Tricia Burdo, PhD; Kathleen V.ÌýFitch, MSN; Emma M.ÌýKileel, MPH; Kenneth Williams, PhD; Carl J.ÌýFichtenbaum, MD; Edgar T.ÌýOverton, MD; Carlos Malvestutto, MD; Judith Aberg, MD; Judith Currier, MD; Craig A.ÌýSponseller, MD; Kathleen Melbourne, PharmD; Michelle Floris-Moore, MD; Cornelius Van Dam, MD; Michael C.ÌýKeefer, MD; Susan L.ÌýKoletar, MD; Pamela S.ÌýDouglas, MD; Heather Ribaudo, PhD; Thomas Mayrhofer, PhD; Steven K.ÌýGrinspoon, MD; REPRIEVE trial
open access
ÁñÁ«ÊÓƵ Netw Open. 2021; 4(6):e2114923. 10.1001/jamanetworkopen.2021.14923
This cohort study examines the prevalence of coronary artery disease (CAD) among adults with well-controlled HIV and low to moderate risk of atherosclerotic cardiovascular disease using computed tomography angiography and assessment of inflammation and immune activation biomarkers.